MedTrace Logo

Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients

NCT01298960 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-02-12

No results posted yet for this study

Summary

Experimental study to evaluate if rGH addition to a standard controlled ovarian stimulation treatment improves ovarian response in women with previous poor ovarian response.

Conditions

  • Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer

Interventions

DRUG

Somatropin

0.1 IU/Kg/day from day one of stimulation until rHCG triggering

Sponsors & Collaborators

  • Fundacion Dexeus

    lead OTHER

Principal Investigators

  • Pedro N Barri, PhD, MD · Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus

  • Buenaventura Coroleu, PhD. MD · Departament of Obstetrics, Gyneacology and Reproductive Medine, Institut Universitari Dexeus

  • Marta Devesa, MD · Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus

  • Francisca Martinez, PhD. MD · Department of Obstetrics, Gyneacology and Reproductive Medicine, Institut Universitari Dexeus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298960 on ClinicalTrials.gov